Evidence map›Paper›PMID 39158464›Full record

ArticleCancer2024

Assessing sociodemographic and regional disparities in Oncotype DX Genomic Prostate Score uptake.

Nita H Mukand, Ekaterina Chirikova, Daphne Lichtensztajn, Serban Negoita, Tamer Aboushwareb, John Bennett, James D Brooks, John T Leppert, Benjamin I Chung, Christopher Li and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Cancer statistics, 2025.CA: a cancer journal for clinicians
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Nita H MukandDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0001-8467-5731
Ekaterina ChirikovaDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
Daphne LichtensztajnGreater Bay Area Cancer Registry, University of California San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0003-2906-3868
Serban NegoitaSurveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, Maryland, USA.ORCID https://orcid.org/0000-0002-9327-9519
Tamer AboushwarebPacific Edge Limited, Dunedin, New Zealand.
John BennettExact Sciences, Redwood City, California, USA.
James D BrooksDepartment of Urology, Stanford Medicine, Palo Alto, California, USA.
John T LeppertDepartment of Urology, Stanford Medicine, Palo Alto, California, USA.ORCID https://orcid.org/0000-0001-9980-3863
Benjamin I ChungDepartment of Urology, Stanford Medicine, Palo Alto, California, USA.
Christopher LiCancer Surveillance System, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID https://orcid.org/0000-0003-1543-0743
Stephen M SchwartzCancer Surveillance System, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Susan T GershmanMassachusetts Department of Public Health, Boston, Massachusetts, USA.
Tabassum InsafBureau of Cancer Epidemiology, New York State Health Department, Albany, New York, USA.ORCID https://orcid.org/0000-0003-4725-2515
Bozena M MorawskiCancer Data Registry of Idaho, Boise, Idaho, USA.
Antionette StroupNew Jersey Cancer Registry, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
Xiao-Cheng WuLouisiana Tumor Registry, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.ORCID https://orcid.org/0000-0003-3663-5027
Jennifer A DohertyUtah Cancer Registry, University of Utah, Salt Lake City, Utah, USA.ORCID https://orcid.org/0000-0002-1454-8187
Valentina I PetkovSurveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, Maryland, USA.
Joao Paulo ZambonMDxHealth, Irvine, California, USA.
Scarlett Lin GomezDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0002-5143-4867
Iona ChengDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.

Funding

Translational Epidemiology - Training for Research on Aging and Chronic diseaseT32AG049663 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Elizabeth Rose Mayeda, Mark J Pletcher · 2016 to 2026
$5.8M
UCSF Data Science Training to Advance Behavioral and Social Science Expertise for Health Research (DaTABASE) ProgramT32MD015070 · NIMHD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI William Brown III, Yulin Hswen · 2020 to 2026
$1.7M
Centers for Disease Control and Prevention's National Program of Cancer Registries 5NU58DP006344National Institute on Aging of the National Institutes of Health T32AG049663NCCDPHP CDC HHS NU58DP006344NCI NIH HHS HHSN261201800009CNCI NIH HHS HHSN261201800009INCI NIH HHS HHSN261201800015CNCI NIH HHS HHSN261201800015INCI NIH HHS HHSN261201800032CNCI NIH HHS HHSN261201800032INIA NIH HHS T32 AG049663NIMHD NIH HHS T32 MD015070NIMHD NIH HHS T32MD015070
6 · The paper itself

Abstract

backgroundThe Oncotype DX Genomic Prostate Score (ODX-GPS) is a gene expression assay that predicts disease aggressiveness. The objective of this study was to identify sociodemographic and regional factors associated with ODX-GPS uptake.

methodsData from Surveillance Epidemiology and End Results registries on men with localized prostate cancer with a Gleason score of 3 + 3 or 3 + 4, PSA ≤20 ng/mL, and stage T1c to T2c disease from 2013 through 2017 were linked with ODX-GPS data. Census-tract level neighborhood socioeconomic status (nSES) quintiles were constructed using a composite socioeconomic score. Multivariable logistic regression was used to estimate the associations of ODX-GPS uptake with age at diagnosis, race and ethnicity, nSES, geographic region, insurance type, and marital status, accounting for National Comprehensive Cancer Network risk group, year of diagnosis, and clustering by census tract.

resultsAmong 111,434 eligible men, 5.5% had ODX-GPS test uptake. Of these, 78.3% were non-Hispanic White, 9.6% were Black, 6.7% were Hispanic, and 3.6% were Asian American. Black men had the lowest odds of ODX-GPS uptake (odds ratio, 0.70; 95% confidence interval [CI], 0.63-0.76). Those in the highest versus lowest quintile of nSES were 1.64 times more likely (95% CI, 1.38-2.94) to have ODX-GPS uptake. The odds of ODX-GPS uptake were statistically significantly higher among men residing in the Northeast, West, and Midwest compared to the South.

conclusionsDisparities in ODX-GPS uptake by race, ethnicity, nSES, and geographical region were identified. Concerted efforts should be made to ensure that this clinical test is equitably available.

Indexed as

Prostatic NeoplasmsAgedGenomicsHealthcare DisparitiesHumansMaleMiddle AgedNeoplasm GradingSEER ProgramSocial ClassSociodemographic FactorsSocioeconomic FactorsUnited Statesgenomic medicinehealth inequitieshealth services accessibilityprostatic neoplasmssocial determinants of healthsocioeconomic disparities and health

Identifiers

PMID39158464
PMCPMC12688416

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.